“This quarter’s progress clearly demonstrates our commitment to our goals of growing and diversifying the business. With a strong balance sheet, the technological superiority of our devices and the strength of our core business infrastructure as the foundation for success, we believe the Company is poised for growth.”
Second Quarter Financial Results
Revenue for the second quarter 2012 was $27.4 million, a decrease of 13.2% compared to $31.6 million in the second quarter 2011. Despite an increase in overall patient volume, patient services revenue declined $3.5 million primarily due to a shift in product mix to event and Holter monitoring which carry a lower reimbursement rate. Additionally, product revenue declined $0.7 million with lower volume due to unusually high sales in the first half of 2011 following the acquisition of Biotel. For the three months ended June 30, 2012, patient revenue was comprised of 43% Medicare and 57% commercial, and MCOT TM patient volume was comprised of 53% Medicare and 47% commercial.
Gross profit for the second quarter 2012 decreased to $16.7 million, or 60.9% of revenue, compared to $18.6 million, or 58.9% of revenue, in the second quarter of 2011. Gross profit for the second quarter 2012 on an adjusted basis was $17.0 million, or 62.0% of revenue, excluding $0.3 million related to restructuring and other nonrecurring charges. The increase in adjusted gross profit percentage was primarily related to the impact of cost reductions implemented at the end of 2011 and lower depreciation.On a GAAP basis, operating expenses for the second quarter 2012 were $18.4 million, a decrease of 15.1% compared to $21.7 million in the second quarter 2011. Operating expenses on an adjusted basis were $17.4 million, a 12.3% decline compared to $19.8 million for the prior year quarter, excluding $1.0 million in the second quarter 2012 and $1.9 million in the second quarter 2011 related to restructuring and other nonrecurring charges. The decrease in operating expenses was driven by the implementation of cost reductions at the end of 2011. These reductions were partially offset by the addition of ECG Scanning’s operating expenditures in the quarter.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV